The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChorBy: AmnioChor Inc. AmnioChor’s technology allows cryopreservation of the amniotic membrane of the placenta, and the human stem cells living within those tissues. Amnion is a well-established source of multipotent stem cells used in a large variety of treatment modalities. Studies underlying AmnioChor’s technologies were performed by Dale Woodbury, PhD and Akiva Marcus, MD, PhD at the Ira B. Black Center for Stem Cell Research and the Department of Neuroscience and Cell Biology at Robert Wood Johnson Medical School, now part of Rutgers University. AmnioChor has an exclusive license for this technology. AmnioChor’ Bruce Stroever, President and CEO of MTF, said, “MTF has been involved with placental tissue recovery and the provision of amniotic tissues for several years. We believe that AmnioChor has technologies that may help us to continue to provide the highest quality amniotic tissues. We are equally pleased to have the opportunity to support technologies developed by the medical school in our own state – Rutgers University”. About the Musculoskeletal Transplant Foundation The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987, MTF has received tissue from more than 100,000 donors and distributed more than 6 million grafts for transplantation. For more information, visit www.mtf.org Contact AmnioChor AmnioChor expanded its executive offices early this year to become a founding member of the new MATTER Chicago healthcare incubator group, and continues to seek investors and strategic partners in the US and globally. For more information go to www.amniochor.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse |